Over 90 percent of people with Huntington’s disease develop chorea. Learn about FDA-approved VMAT2 inhibitors, off-label medications, and lifestyle strategies to manage involuntary movements.

Benign hereditary chorea is a rare disorder that affects movement. The condition starts in infancy or childhood. Although it affects movement, it can also cause additional problems in other organs, ...

Please provide your email address to receive an email when new articles are posted on . Most patients with chorea and antiphospholipid antibody were women, with chorea onset at an average age of 22.8 ...

This type of medication can help manage the uncontrolled movements that can occur with Huntington’s disease. Huntington’s disease is a neurodegenerative disorder that causes a progressive breakdown of ...

The drug valbenazine statistically improves chorea, a movement disorder commonly associated with Huntington's disease, when compared to a placebo, according to a recent international study led by ...

Motor symptoms of Huntington's disease (HD) are so central to the genetic neurodegenerative disease that it was long called Huntington's chorea. However, they're often untreated, despite a growing ...

A drug currently approved for tardive dyskinesia (TD) is also effective at treating Huntington's disease (HD)–associated chorea, a movement disorder that affects most patients with HD, new phase 3 ...

Symptoms of ARF tend to present themselves 1-3 weeks after infection. A high index of suspicion for ARF must be maintained, especially because a single diagnostic tool does not exist. Thomas D. Jones ...

A case report indicates that valbenazine may be an effective therapy for chorea-ballism associated with tardive dyskinesia. Valbenazine has therapeutic potential to improve chorea-ballism associated ...

Huntington’s disease, also known as Huntington’s chorea and formerly called “Saint Vitus’ dance,” is a rare, hereditary disorder of the central nervous system. It is characterized by jerky movements ...

SAN DIEGO, Aug. 18, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration (FDA) has approved INGREZZA® (valbenazine) capsules for the ...